CL2020001062A1 - Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. - Google Patents

Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.

Info

Publication number
CL2020001062A1
CL2020001062A1 CL2020001062A CL2020001062A CL2020001062A1 CL 2020001062 A1 CL2020001062 A1 CL 2020001062A1 CL 2020001062 A CL2020001062 A CL 2020001062A CL 2020001062 A CL2020001062 A CL 2020001062A CL 2020001062 A1 CL2020001062 A1 CL 2020001062A1
Authority
CL
Chile
Prior art keywords
methods
sulfoxides
compounds
sulfones
bicyclic
Prior art date
Application number
CL2020001062A
Other languages
English (en)
Inventor
Huifen Chen
Snahel Patel
Gregory Hamilton
Craig Stivala
Blake Daniels
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2020001062A1 publication Critical patent/CL2020001062A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PROPORCIONAN COMPUESTOS QUE TIENEN LA FÓRMULA GENERAL I: EN LA QUE R1, R B1, RB2, N, P, Q, EL ANILLO A Y EL ANILLO B SON COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO, COMPOSICIONES FARMACÉUTICAS QUE INCLUYEN LOS COMPUESTOS Y MÉTODOS PARA USAR LOS COMPUESTOS. LOS COMPUESTOS DE FÓRMULA (I) SON INHIBIDORES DE LA QUINASA RIP1 Y, POR LO TANTO, SON ÚTILES EN EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS, NEURODEGENERATIVOS Y DE OTRO TIPO.
CL2020001062A 2017-10-31 2020-04-20 Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. CL2020001062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762579392P 2017-10-31 2017-10-31

Publications (1)

Publication Number Publication Date
CL2020001062A1 true CL2020001062A1 (es) 2020-08-21

Family

ID=64051580

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001062A CL2020001062A1 (es) 2017-10-31 2020-04-20 Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.

Country Status (21)

Country Link
US (2) US11072617B2 (es)
EP (1) EP3704097B1 (es)
JP (1) JP2021501183A (es)
KR (1) KR20200083515A (es)
CN (1) CN111278809A (es)
AR (1) AR113811A1 (es)
AU (1) AU2018360270A1 (es)
BR (1) BR112020008446A2 (es)
CA (1) CA3078688A1 (es)
CL (1) CL2020001062A1 (es)
CO (1) CO2020003475A2 (es)
CR (1) CR20200168A (es)
IL (1) IL273847A (es)
MA (1) MA50503A (es)
MX (1) MX2020003451A (es)
PE (1) PE20211247A1 (es)
PH (1) PH12020550537A1 (es)
RU (1) RU2020115915A (es)
SG (1) SG11202002877RA (es)
TW (1) TW201922748A (es)
WO (1) WO2019086494A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6890179B2 (ja) 2016-12-02 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式アミド化合物及びその使用方法
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
TW202340182A (zh) 2021-11-11 2023-10-16 美商健臻公司 做為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
EP0652775B1 (en) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
US6080772A (en) * 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
JP2002512628A (ja) 1997-06-13 2002-04-23 スージェン・インコーポレーテッド タンパク質チロシン酵素関連の細胞信号伝達を調節するための新規ヘテロアリール化合物
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
AU2003302676A1 (en) 2002-12-03 2004-06-23 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
ATE410161T1 (de) 2003-05-02 2008-10-15 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
MX2014005285A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.
MX2014013407A (es) 2012-05-22 2014-11-26 Hoffmann La Roche Dipiridilaminas sustituidas y uso de las mismas.
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
CA2907912A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
TWI622587B (zh) 2013-05-01 2018-05-01 赫孚孟拉羅股份公司 二雜芳基化合物及其用途
CN105473554B (zh) 2013-07-10 2019-08-13 沃泰克斯药物股份有限公司 作为离子通道调节剂的稠合的哌啶酰胺类
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
CA2935612A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
EP3268373B1 (en) 2015-03-09 2022-04-27 F. Hoffmann-La Roche AG Tricyclic dlk inhibitors and uses thereof
TWI763630B (zh) 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
US10709692B2 (en) * 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
MY196648A (en) * 2016-02-05 2023-04-27 Denali Therapeutics Inc Inhibitors of Receptor-Interacting Protein Kinase 1
JP6890179B2 (ja) 2016-12-02 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式アミド化合物及びその使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
BR112020007067A2 (pt) 2017-10-11 2020-10-06 F. Hoffmann-La Roche Ag compostos bicíclicos para uso como inibidores rip1 quinase

Also Published As

Publication number Publication date
AU2018360270A1 (en) 2020-03-26
AR113811A1 (es) 2020-06-10
CO2020003475A2 (es) 2020-04-24
WO2019086494A1 (en) 2019-05-09
CR20200168A (es) 2020-07-12
IL273847A (en) 2020-05-31
US20190127382A1 (en) 2019-05-02
US11072617B2 (en) 2021-07-27
MX2020003451A (es) 2020-08-03
CA3078688A1 (en) 2019-05-09
EP3704097B1 (en) 2023-10-25
CN111278809A (zh) 2020-06-12
PE20211247A1 (es) 2021-07-13
US20230002391A1 (en) 2023-01-05
SG11202002877RA (en) 2020-04-29
PH12020550537A1 (en) 2021-03-22
TW201922748A (zh) 2019-06-16
MA50503A (fr) 2020-09-09
BR112020008446A2 (pt) 2020-12-29
EP3704097C0 (en) 2023-10-25
RU2020115915A3 (es) 2022-05-06
RU2020115915A (ru) 2021-12-01
JP2021501183A (ja) 2021-01-14
KR20200083515A (ko) 2020-07-08
EP3704097A1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CR20180058A (es) Nuevos derivados de fenoximetilo
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CL2019001339A1 (es) Inhibidores de la magl.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CO2019005038A2 (es) Inhibidores de magl
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CL2020000101A1 (es) Compuestos de cetonas bicíclicas y métodos de uso de los mismos.
CR20170438A (es) Desacetoxitubulisina h y análogos de esta
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2019002583A1 (es) Inhibidores duales de magl y faah.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer
BR112016020135A8 (pt) mistura de composto, seus usos, composição farmacêutica, e conjunto (kit)
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores